PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG

Ítems similars

• PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
  per: H. Chang, et al.
  Publicat: (2022-06-01)
• Role of eltrombopag in severe aplastic anemia treatment in children
  per: Min-Yu Su, et al.
  Publicat: (2021-11-01)
• The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
  per: Ayşe Işık, et al.
  Publicat: (2013-09-01)
• PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
  per: Zhuxin Zhang, et al.
  Publicat: (2023-08-01)
• Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
  per: Yoshitaka Zaimoku, et al.
  Publicat: (2021-04-01)